Feb 6 (Reuters) - AstraZeneca AZN.L and Daiichi Sankyo's 4568.T breast cancer treatment Enhertu, might be part of a Chinese investigation into the import of AstraZeneca's cancer medications, Chief Executive Pascal Soriot told media on Thursday.
Earlier in the day, the company said it could face a fine of up to $4.5 million in China for possibly unpaid import taxes on two other cancer drugs, Imfinzi and Imjudo. The company first reported this investigation in November.